SEC Form 4 · accession 0001144204-15-035879
TG THERAPEUTICS, INC. · TGTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael S Weiss
Officer — See Remarks · Director · 10% Owner
Period of report
Jun 4, 2015
Accepted (ET)
Jun 5, 2015 · 7:08 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001001316
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| COMMON STOCKF1,F2 | Jun 4, 2015 | A | 337,257 | $0.00 | A | 8,726,633 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Reflects a grant of restricted shares that will vest according to the following schedule: 25% on January 1, 2018; 25% on January 1, 2019; and 50% on the later to occur of: (a) the date that the Company's Market Capitalization is $100 million greater than the Market Capitalization on December 30, 2014 and (b) the January 1, 2020. Mr. Weiss elected to defer the 337,257 shares from a larger grant of 605,860 shares on December 30, 2014.
- F2Includes shares of restricted Common Stock, which vest over various time periods. Includes 33,334 warrants to purchase Common Stock at $2.25, exercisable through December 31, 2016. Finally, also included in Mr. Weiss' beneficial ownership are 4,524,560 shares of Common Stock issued to Opus Point Partners, LLC, of which Mr. Weiss is a co-founder, managing partner, and principal and beneficially owns a 50% interest.
Remarks
Executive Chairman, Interim CEO and President